Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Buy" from Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been given a consensus recommendation of "Buy" by the eleven ratings firms that are currently covering the firm, MarketBeat.com reports. Ten analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $57.10.

Several analysts have recently commented on MIRM shares. Robert W. Baird raised their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Citigroup increased their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Leerink Partners lifted their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Finally, HC Wainwright reiterated a "buy" rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th.

Mirum Pharmaceuticals Stock Performance

MIRM traded down $0.06 during trading on Thursday, hitting $42.00. The stock had a trading volume of 305,985 shares, compared to its average volume of 405,737. The firm has a market capitalization of $2.02 billion, a P/E ratio of -20.79 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals has a twelve month low of $23.14 and a twelve month high of $48.89. The company's 50-day moving average price is $42.93 and its 200 day moving average price is $40.62.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business's revenue was up 89.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.57) earnings per share. On average, equities research analysts forecast that Mirum Pharmaceuticals will post -1.46 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Jolanda Howe sold 750 shares of the firm's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the sale, the senior vice president now directly owns 2,926 shares in the company, valued at approximately $125,291.32. This trade represents a 20.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Christopher Peetz sold 7,489 shares of the business's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the transaction, the chief executive officer now directly owns 119,359 shares in the company, valued at approximately $5,110,952.38. The trade was a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,737 shares of company stock valued at $556,098. 22.87% of the stock is currently owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp grew its stake in Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company's stock valued at $69,955,000 after purchasing an additional 297,511 shares in the last quarter. Rice Hall James & Associates LLC grew its position in shares of Mirum Pharmaceuticals by 6.9% during the second quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company's stock worth $7,854,000 after buying an additional 14,843 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Mirum Pharmaceuticals by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company's stock worth $12,798,000 after buying an additional 17,149 shares during the last quarter. Geode Capital Management LLC raised its holdings in Mirum Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company's stock valued at $36,519,000 after acquiring an additional 29,017 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Mirum Pharmaceuticals by 48.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,000 shares of the company's stock valued at $4,889,000 after acquiring an additional 46,506 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.